125 related articles for article (PubMed ID: 29620223)
1. Resveratrol decreases Rad51 expression and sensitizes cisplatin‑resistant MCF‑7 breast cancer cells.
Leon-Galicia I; Diaz-Chavez J; Albino-Sanchez ME; Garcia-Villa E; Bermudez-Cruz R; Garcia-Mena J; Herrera LA; García-Carrancá A; Gariglio P
Oncol Rep; 2018 Jun; 39(6):3025-3033. PubMed ID: 29620223
[TBL] [Abstract][Full Text] [Related]
2. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells.
Leon-Galicia I; Diaz-Chavez J; Garcia-Villa E; Uribe-Figueroa L; Hidalgo-Miranda A; Herrera LA; Alvarez-Rios E; Garcia-Mena J; Gariglio P
Eur J Cancer Prev; 2013 Jan; 22(1):11-20. PubMed ID: 22644231
[TBL] [Abstract][Full Text] [Related]
4. Increased γ-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin.
Adam-Zahir S; Plowman PN; Bourton EC; Sharif F; Parris CN
Chemotherapy; 2014; 60(5-6):310-20. PubMed ID: 26138778
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of pomegranate extract in MCF-7 breast cancer cells are associated with reduced DNA repair gene expression and induction of double strand breaks.
Shirode AB; Kovvuru P; Chittur SV; Henning SM; Heber D; Reliene R
Mol Carcinog; 2014 Jun; 53(6):458-70. PubMed ID: 23359482
[TBL] [Abstract][Full Text] [Related]
6. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
7. Induction of p53 Phosphorylation at Serine 20 by Resveratrol Is Required to Activate p53 Target Genes, Restoring Apoptosis in MCF-7 Cells Resistant to Cisplatin.
Hernandez-Valencia J; Garcia-Villa E; Arenas-Hernandez A; Garcia-Mena J; Diaz-Chavez J; Gariglio P
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30142917
[TBL] [Abstract][Full Text] [Related]
8. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
Deng Y; Guo W; Xu N; Li F; Li J
Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis induction in human breast cancer cell lines by synergic effect of raloxifene and resveratrol through increasing proapoptotic genes.
Mirzapur P; Khazaei MR; Moradi MT; Khazaei M
Life Sci; 2018 Jul; 205():45-53. PubMed ID: 29705353
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization effects of berberine on human breast cancer cells.
Wang J; Liu Q; Yang Q
Int J Mol Med; 2012 Nov; 30(5):1166-72. PubMed ID: 22895634
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
Cousineau I; Abaji C; Belmaaza A
Cancer Res; 2005 Dec; 65(24):11384-91. PubMed ID: 16357146
[TBL] [Abstract][Full Text] [Related]
12. Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy.
Díaz-Chávez J; Fonseca-Sánchez MA; Arechaga-Ocampo E; Flores-Pérez A; Palacios-Rodríguez Y; Domínguez-Gómez G; Marchat LA; Fuentes-Mera L; Mendoza-Hernández G; Gariglio P; López-Camarillo C
PLoS One; 2013; 8(5):e64378. PubMed ID: 23724044
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
Liu X; Han EK; Anderson M; Shi Y; Semizarov D; Wang G; McGonigal T; Roberts L; Lasko L; Palma J; Zhu GD; Penning T; Rosenberg S; Giranda VL; Luo Y; Leverson J; Johnson EF; Shoemaker AR
Mol Cancer Res; 2009 Oct; 7(10):1686-92. PubMed ID: 19825992
[TBL] [Abstract][Full Text] [Related]
14. Targeting RAD51 enhances chemosensitivity of adult T‑cell leukemia‑lymphoma cells by reducing DNA double‑strand break repair.
Yang M; Tian X; Fan Z; Yu W; Li Z; Zhou J; Zhang W; Liang A
Oncol Rep; 2019 Dec; 42(6):2426-2434. PubMed ID: 31638261
[TBL] [Abstract][Full Text] [Related]
15. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
[TBL] [Abstract][Full Text] [Related]
16. Artesunate sensitizes ovarian cancer cells to cisplatin by downregulating RAD51.
Wang B; Hou D; Liu Q; Wu T; Guo H; Zhang X; Zou Y; Liu Z; Liu J; Wei J; Gong Y; Shao C
Cancer Biol Ther; 2015; 16(10):1548-56. PubMed ID: 26176175
[TBL] [Abstract][Full Text] [Related]
17. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
18. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W
Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha.
Levenson AS; Gehm BD; Pearce ST; Horiguchi J; Simons LA; Ward JE; Jameson JL; Jordan VC
Int J Cancer; 2003 May; 104(5):587-96. PubMed ID: 12594813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
